MNX1‐AS1 is a novel biomarker for predicting clinical progression and poor prognosis in lung adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MNX1‐AS1 is a novel biomarker for predicting clinical progression and poor prognosis in lung adenocarcinoma

Published:2018-12-02 Issue:5 Volume:120 Page:7222-7228
ISSN:0730-2312
Container-title:Journal of Cellular Biochemistry
language:en
Short-container-title:J Cell Biochem

Author:

Yang Ronghua¹,Wang Lei²,Han Minghui³^ORCID

Affiliation:

1. Department of Thoracic Surgery The Affiliated Hospital of Qingdao University Qingdao Shandong China

2. Department of Thoracic Surgery The Second Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang China

3. Department of Thoracic Surgery Qingdao Huangdao District Central Hospital Qingdao Shandong China

Publisher

Wiley

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcb.27996

Reference17 articles.

1. Global cancer statistics, 2012

2. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small–Cell Lung Cancer and Its Effects on Survival

3. Lung Cancer in China

4. International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising

5. Non–Small Cell Lung Cancer, Version 6.2015

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers;Journal of Oncology;2022-09-21

2. Activation of MYO1G by lncRNA MNX1-AS1 Drives the Progression in Lung Cancer;Molecular Biotechnology;2022-07-11

3. LncRNA MNX1-AS1: A novel oncogenic propellant in cancers;Biomedicine & Pharmacotherapy;2022-05

4. The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis;Frontiers in Genetics;2022-04-05

5. Identification and Validation of 7-lncRNA Signature of Epigenetic Disorders by Comprehensive Epigenetic Analysis;Disease Markers;2022-02-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3